Increased survival time or better quality of life? Trade-off between benefits and adverse events in the systemic treatment of cancer.
Vicente ValentíJ RamosC PérezL CapdevilaI RuizL TikhomirovaM SánchezI JuezM LloberaE SopenaJ RubióR SalazarPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)
The three attributes (SV, QoL, and AEs) are considered in the same way by cancer patients to make choices on their STC. On the contrary, when placed as hypothetical patients, physicians prefer for themselves those treatments that provide more SV.